Medpace (NASDAQ:MEDP) Rating Increased to Hold at Leerink Partnrs

Leerink Partnrs upgraded shares of Medpace (NASDAQ:MEDP) to a hold rating in a research report report published on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Medpace’s Q1 2025 earnings at $3.03 EPS, Q2 2025 earnings at $2.96 EPS, Q3 2025 earnings at $2.92 EPS, Q4 2025 earnings at $3.16 EPS, FY2025 earnings at $12.07 EPS, FY2026 earnings at $12.76 EPS, FY2027 earnings at $13.90 EPS and FY2028 earnings at $15.81 EPS.

Other equities analysts have also recently issued reports about the company. Leerink Partners initiated coverage on Medpace in a research report on Monday. They issued a “market perform” rating and a $330.00 price objective on the stock. Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Price Performance

MEDP opened at $317.65 on Monday. The firm has a market cap of $9.68 billion, a PE ratio of 25.15, a P/E/G ratio of 3.81 and a beta of 1.47. The stock has a 50-day moving average price of $336.81 and a 200-day moving average price of $339.41. Medpace has a 1 year low of $302.01 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, sell-side analysts anticipate that Medpace will post 12.29 EPS for the current year.

Institutional Investors Weigh In On Medpace

A number of large investors have recently made changes to their positions in the company. Raymond James Trust N.A. grew its position in Medpace by 34.6% during the third quarter. Raymond James Trust N.A. now owns 754 shares of the company’s stock valued at $252,000 after buying an additional 194 shares during the period. Swedbank AB bought a new stake in shares of Medpace during the 3rd quarter valued at $7,477,000. Centaurus Financial Inc. grew its position in shares of Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after acquiring an additional 29 shares during the period. Fisher Asset Management LLC increased its stake in shares of Medpace by 6.9% in the 3rd quarter. Fisher Asset Management LLC now owns 124,399 shares of the company’s stock worth $41,524,000 after purchasing an additional 8,012 shares in the last quarter. Finally, Independent Advisor Alliance raised its holdings in Medpace by 16.7% in the 3rd quarter. Independent Advisor Alliance now owns 941 shares of the company’s stock worth $314,000 after purchasing an additional 135 shares during the period. 77.98% of the stock is currently owned by institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.